secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2022-09-15T23:59:59+00:00
Accession:  0001140361-22-033411
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 3.03, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics formed via Caladrius-Cend merger; ~$76M cash, ticker LSTA
-----------------------------------------------------------------------------

- Merger closed 9/15/22: Caladrius issued 0.5338 shares per Cend share after 1:15 reverse split; post-merger shares ~7.82M.
- Former Caladrius stockholders own ~52%, former Cend stockholders ~48% of combined company.
- Combined cash and investments ~$76M; focus on CendR Platform oncology pipeline and existing programs.
- Name changed to Lisata Therapeutics; ticker LSTA on Nasdaq; former ticker CLBS discontinued.
- Board expanded with four Cend designees; David Slack named President & CBO; leadership team includes CEO David Mazzo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/brhc10041800_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-033411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer